United States Next Generation Sequencing Market Size, Share & Forecast (2024–2032)

Market Overview

The United States Next Generation Sequencing (NGS) market is poised to witness explosive growth, expected to expand from US$ 3.16 Billion in 2023 to a staggering US$ 13.75 Billion by 2032, registering a CAGR of 17.75% during the forecast period 2024 to 2032. This remarkable growth is attributed to rapid advancements in genomics technology, a surge in biotechnological applications, increased demand for personalized medicine, and greater public and private investments in biomedical research.

What is Next Generation Sequencing (NGS)?

Next Generation Sequencing (NGS) is a transformative technology that allows for the rapid sequencing of DNA and RNA, enabling scientists and clinicians to better understand genetic variation, disease mechanisms, and biological functions. Unlike traditional sequencing, NGS can process millions of DNA fragments simultaneously, making it an efficient and cost-effective tool for genomics research, diagnostics, and therapeutics.

Key Market Drivers

1. Surge in Personalized Medicine & Targeted Therapies

NGS has become the cornerstone of personalized healthcare by allowing clinicians to tailor treatment plans based on an individual's genetic profile. In oncology, this technology enables precise tumor profiling and drug responsiveness, improving treatment efficacy and minimizing side effects.

2. Technological Advancements in Sequencing

Rapid developments in sequencing platforms, bioinformatics tools, and data interpretation software are continuously reducing turnaround times and cost per genome. Companies like Illumina, Thermo Fisher Scientific, and QIAGEN are investing heavily in R&D to innovate NGS technologies. The acquisition of Verogen by QIAGEN in January 2023 exemplifies the integration of NGS into forensic and human identification applications.

3. Expanding Applications Beyond Healthcare

NGS is no longer limited to healthcare. Its applications extend to agriculture (for improving crop yield and disease resistance), environmental sciences (ecosystem biodiversity tracking), and animal research. This multi-sectoral utility is broadening the commercial viability of NGS in the U.S.

4. Rising Cancer Incidence in the U.S.

According to the American Cancer Society, approximately 2,001,140 new cancer cases and 611,720 deaths are projected in 2024 alone. Oncology remains one of the largest segments utilizing NGS for cancer detection, mutation tracking, and treatment planning.

5. Government Support & Public Health Initiatives

The U.S. government has made significant investments in genomic surveillance. Under the American Rescue Plan, $1.7 billion was allocated in 2022 for strengthening pathogen genomic surveillance. CDC’s support of NGS-based public health labs ensures long-term growth and broader accessibility of genomic technologies.

Related Report

Video Game Market

Europe Next Generation Sequencing Market

United Kingdom Video Game Market

Market Challenges

1. High Cost of Implementation

Despite falling sequencing costs, the initial investment for NGS instruments, reagents, infrastructure, and skilled professionals remains prohibitively high, especially for small hospitals and labs. Furthermore, inconsistent insurance reimbursement policies limit the adoption of NGS diagnostics.

2. Data Management, Interpretation & Privacy

NGS generates massive datasets, requiring robust storage, computing infrastructure, and bioinformatics expertise. Privacy concerns related to sensitive genetic data add further complexity, necessitating strict compliance with laws like HIPAA.

Key Market Segments

By Product:

• Instruments
• Reagents & Consumables (largest share due to recurring usage in testing workflows)
• Services

By Application:

• Diagnostics
• Drug Discovery
• Agriculture & Animal Research
• Personalized Medicine & Genetic Screening
• Others

By Technology:

• Sequencing by Synthesis (SBS) (dominant segment)
• Ion Semiconductor Sequencing
• Nanopore Sequencing
• Single-Molecule Real-Time (SMRT) Sequencing
• Others

By End-User:

• Academic and Clinical Research Centers
• Pharmaceutical and Biotechnology Companies
• Hospitals and Clinics
• Others

In-Depth Segment Insights

United States Reagents & Consumables Market

The reagents and consumables segment plays a vital role in maintaining sequencing continuity, particularly in clinical diagnostics and academic research. The demand for library prep kits, enzymes, and sample prep solutions continues to surge, but supply chain disruptions and regulatory approvals can pose growth bottlenecks.

NGS in U.S. Diagnostics Market

NGS has redefined the diagnostic landscape—especially for cancer, rare diseases, and infectious pathogens. With increasing use in NIPT and liquid biopsies, the diagnostics segment is expanding rapidly. Yet, regulatory hurdles and coverage restrictions must be addressed for widespread clinical integration.

NGS in Drug Discovery

NGS plays a pivotal role in biomarker discovery, pharmacogenomics, and target validation. With increasing investments from biotech and pharma companies, NGS is accelerating drug development pipelines. However, data interpretation challenges and regulatory delays can affect commercialization timelines.

Sequencing by Synthesis (SBS) Technology

Illumina’s SBS platform remains the market leader in high-throughput sequencing due to its accuracy and scalability. Recent innovations focus on extending read lengths and simplifying workflows, further solidifying its dominance in the U.S. research market.

NGS in U.S. Hospitals and Clinics

While leading hospitals are incorporating NGS into routine patient care, community clinics struggle with affordability and manpower. Key developments, such as Complete Genomics’ U.S. expansion in Jan 2025, aim to decentralize and lower the cost of genomic testing.

Recent Strategic Developments

• Jan 2024 – Illumina & Janssen collaborated on a residual disease assay targeting circulating tumor DNA.
• May 2023 – Pfizer & Thermo Fisher Scientific teamed up to increase NGS testing access across 30+ developing nations.
• April 2023 – Agilent Technologies introduced a novel NGS oncology assay.
• Sept 2023 – QIAGEN partnered with Neuron23 for developing Parkinson's-focused diagnostic assays.
• April 2022 – Thermo Fisher Scientific launched its Ion Torrent Genexus Dx Integrated Sequencer, providing results within 24 hours.

Key Players Covered (10 Major Companies)

1. Illumina Inc.
2. Thermo Fisher Scientific
3. Pacific Biosciences of California
4. QIAGEN N.V.
5. Roche
6. Bio-Rad Laboratories, Inc.
7. Takara Bio Inc.
8. Hamilton Company
9. Geneious
10. BioMérieux SA

Each company profile includes:

• Overview
• Key Personnel
• Recent Developments
• Product Launches
• Revenue Trends

United States NGS Market – Forecast Summary

Customization & Report Offerings

We offer:

• Segment-Specific Analysis
• Region/Country Specific Insights
• Market Entry Strategy
• Trade Analysis
• Company Expansion Analysis

Delivery Format: PDF + Excel (PPT/Word editable versions available upon request)
Post-Sale Support: 1-Year Analyst Support
Pricing: Starts from $2,490 (Dashboard) to $3,990 (Corporate License)

Get in Touch

? USA: +1-678-302-0700
? INDIA: +91-120-421-9822
? Email: info@renub.com
? www.renub.com